UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

CLEARPOINT NEURO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-34822**	**58-2394628**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
120 S. Sierra Ave., Suite 100 Solana Beach, California		**92075**
(Address of Principal Executive Offices)		**(Zip Code)**

Registrant's Telephone Number, Including Area Code: 888 287-9109

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value per share	CLPT	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On March 17, 2026, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its financial results for the fourth fiscal quarter and full year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On March 17, 2026, the Company posted an updated investor presentation to its website at http://ir.stockpr.com/clearpointneuro/investor-presentations. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	Press Release dated March 17, 2026
Exhibit 99.2	Investor Presentation dated March 17, 2026
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLEARPOINT NEURO, INC.

Date: March 17, 2026

By: /s/ Danilo D'Alessandro

Danilo D'Alessandro
Chief Financial Officer

Exhibit 99.1

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy

SOLANA BEACH, CA, March 17, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full year ended December 31, 2025.

2025 Full Year and Fourth Quarter Highlights

- Reported fourth quarter revenue of $10.4 million, including $1.2 million of IRRA*flow* revenue, representing 34% overall growth and 19% year-over-year organic growth compared with the fourth quarter of 2024;
- Reported revenue of $37.0 million for the full year 2025, an overall increase of 18% and 14% increase in organic growth over 2024 and signifying the eleventh consecutive year of growth;
- Completed the acquisition of IRRAS Holdings, Inc., in November 2025 expanding the Company's portfolio into neurocritical care, and allowing an expanded set of solutions spanning functional neurosurgery, neurocritical care, and intracranial drug delivery;
- In conjunction with the IRRAS acquisition, entered into an agreement to access an additional $20.0 million in funding under the existing note financing arrangement with Oberland Capital;
- Received EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, expanding the Company's latest operating room navigation platform to EU customers;
- Completed initial development and showcased a prototype of the Company's proprietary robotic neuro-navigation system at the 75th Annual Congress of Neurological Surgeons in Los Angeles in October 2025; and
- Reported cash and cash equivalents totaling $45.9 million as of December 31, 2025.

"Our Company ended 2025 on a high note with the strongest financial quarter of the year, a newly acquired and commercialized neurocritical care product line, and a genuine excitement regarding our 2026 opportunities," commented Joe Burnett, President and CEO at ClearPoint Neuro. "We have invested more than $100 million over the past five years to build a strong foundation, made up of four growing product categories, a vetted pipeline of new development programs, an expanded manufacturing footprint, a thoroughly audited quality system, a collection of global regulatory approvals, an expansive IP portfolio, an installed base of more than 150 global centers, and the cash position and investor base to execute on our strategy. Most importantly, through our unique biologics and drug delivery ecosystem, we have attracted more than 60 active biopharma partners, we are currently supporting more than 25 global clinical trials, and more than 10 of our biopharma partner programs have now been accepted to some form of FDA expedited regulatory review. Our Company has never been in a stronger position than we are right now."

“As we look ahead, we have now entered the next two phases of our growth strategy:”

“The first phase, which we call “Fast. Forward.” is to penetrate an existing $1 billion market opportunity made up of four distinct product segments: 1) pre-commercial drug delivery products and services, 2) neurosurgery navigation and robotics, 3) laser therapy and access, and 4) neurocritical fluid management. We expect all four of these product lines to grow double digits in 2026 through the expansion of our commercial organization, approval of products in new geographies, additional site activations, generation of clinical data, and the execution and launch of new products in our development pipeline.”

“The second phase, which we call “Essential. Everywhere.” is to build a new market that does not yet exist for commercial cell and gene therapy delivery. This is a market in which we believe that the unique ClearPoint Neuro ecosystem will play an essential role. This ecosystem will include brain segmentation tools, predictive drug-delivery modeling, pre-planning and navigation software, frame and robotic delivery options, drug loading and mechanized infusion technologies, an array of cell and gene therapy routes-of-administration, and post procedure quality confirmation software to meticulously track proper delivery. All of these workflow steps will be supported by our talented team of clinical specialists and scientists who will be there in the room, assisting our partners when these new-to-world therapies are first commercialized.”

“For 2026, we now expect revenues to be in the range of $52.0 - $56.0 million. In parallel, we will continue to support our biopharma partners through the global regulatory process, which will generate additive revenue in the years ahead, as we enter the “Essential. Everywhere.” phase.”

Business Outlook

The Company estimates revenue in 2026 to be between $52.0 million and $56.0 million.

Financial Results – Year Ended December 31, 2025

Total revenue was $37.0 million and $31.4 million for the years ended December 31, 2025 and 2024, respectively.

Biologics and drug delivery revenue, which include sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased 10% to $19.0 million for the year ended December 31, 2025, from $17.3 million for the same period in 2024. This increase is attributable to a $1.7 million of higher product revenue resulting from greater demand for disposables as multiple partners progress in their trials.

Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 44% to $14.8 million during the year ended December 31, 2025, from $10.3 million for the same period in 2024. The increase is driven by an increased customer base, additional revenues due to the IRRA*flow* product line acquisition completed in November 2025, and higher sales for new offerings of SmartFrame OR, Prism Laser Therapy, and introduction of our 3.0 operating room software, during the year ended December 31, 2025, compared to the same period in 2024.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, decreased 18% to $3.1 million for the year ended December 31, 2025, from $3.8 million for the same period in 2024, due to a decrease in the placements of ClearPoint navigation capital and software and Prism laser units.

The Company achieved a gross margin of 61% on its sales for 2025, and is broadly in line with gross margin of 61% in the same period in 2024.

Operating expenses were $46.9 million for the full year 2025, compared with $38.9 million for 2024, an increase of 21%. The increase was mainly driven by the integration of IRRAS, higher product and software development costs, acquisition-related expenses, professional services fees, and personnel-related expenses, including share-based compensation, as we increased headcount due to the IRRAS acquisition and to fuel the expansion of the research and development, clinical, and support organizations.

Financial Results – Quarter Ended December 31, 2025

Total revenue was $10.4 million for the three months ended December 31, 2025, in comparison to $7.8 million for the three months ended December 31, 2024.

Biologics and drug delivery revenue, which include sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased 23% to $5.2 million for the three months ended December 31, 2025, from $4.2 million for the same period in 2024. This increase is attributable to $1.1 million of higher product revenue resulting from greater demand for disposables as multiple partners progress in their trials, partially offset by lower service revenue of $0.1 million.

Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 61% to $4.7 million for the three months ended December 31, 2025, from $2.9 million for the same period in 2024. The increase is driven by an increased customer base and additional revenues due to the IRRA*flow* product line acquisition completed in November 2025, during the three months ended December 31, 2025, compared to the same period in 2024.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, decreased 18% to $0.5 million for the three months ended December 31, 2025, from $0.6 million for the same period in 2024.

The Company achieved a gross margin of 62% on its sales for the three months ended December 31, 2025, and is broadly in line with gross margin of 61% in the same period in 2024.

Operating expenses were $13.4 million for the three months ended December 31, 2025, compared with $10.4 million for the same period in 2024, an increase of 30%. The increase was mainly driven by the acquisition of IRRAS and increased professional services fees.

At December 31, 2025, the Company had cash and cash equivalents totaling $45.9 million as compared to $20.1 million at December 31, 2024, with the increase resulting from the net proceeds of the notes payable and stock offering of $51.4 million, and cash acquired as part of the IRRAS acquisition of $1.1 million, partially offset by the use of $23.9 million in cash for operating activities and $1.9 million in cash paid for taxes related to the net share settlement of equity awards.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2025 fourth quarter and full year results on Tuesday, March 17, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=XzyAJzOm. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until April 16, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance; the market opportunity and rate of sales and revenue growth for the Company's products and services, including for the Company's preclinical CRO facility and its products and services, the Company's neuronavigational products, the IRRAflow Active Fluid Exchange System, and the PRISM Laser Therapy System; the Company's expectations for achieving key growth drivers for its sales including its ability to expand its commercial organization, receive regulatory approval for its products in new geographies, activate additional customer sites, generate clinical and economic data to support and expand the adoption rate for its products, and its development of new products; the Company's ability to successfully develop new products for gene and cell therapy delivery, including brain segmentation tools, predictive drug-delivery modeling, new pre-planning and navigation software, frame and robotic delivery options, drug loading and mechanized infusion technologies, cell and gene therapy routes-of-administration, and post procedure quality confirmation software; the adoption of the Company's products and services for use in the delivery of gene and cell therapies; the regulatory approval and commercialization of cell and gene therapies being developed by the Company's biotech Partners; and the Company's expectations for revenues, operating expenses, and management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's biotech Partners' risks related to the ongoing conduct of their clinical studies, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data becomes available that results in a different interpretation then the data already released for gene and cell therapies; risks related to interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval of the biotech Partners' therapies; the limitation or modification of the FDA's eligibility and criteria for its expedited review programs with respect to such therapies; the commercialization and acceptance of gene and cell therapies; the

Company’s biotech Partner’s continued use of the Company’s products and services in their delivery of gene and cell therapies; the Company’s ability to maintain its current relationships with its biotech Partners or enter into relationships with new partners; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to allow for widespread adoption of intracranial administration of gene and cell therapies; risks inherent in the research, development, and regulatory approval of the Company’s new products; the future market for preclinical services and products and the investment required to expand such services, which could divert resources from the Company’s other business operations; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company’s failure to integrate IRRAS into its business in accordance with expectations; deviations from the expected market potential of the IRRAS products; diversion of management’s attention on the integration of IRRAS into its business; macroeconomic and inflationary conditions; regulatory and policy uncertainty; the introduction of or changes in tariffs, sanctions, or trade barriers; changes in monetary policy; geopolitical trends, such as instability, protectionism and economic nationalism; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the availability of additional funding to support the Company's research and development programs and the expansion of its commercial organization; the ability of the Company to manage the growth of its business; and the Company’s ability to attract and retain its key employees. For a detailed description of the Company’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:

Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com

CLEARPOINT NEURO, INC.

Consolidated Statements of Operations
(in thousands, except for share and per share data)

	Year Ended December 31,	
	2025	**2024**
Revenue:		
Product revenue	$ 23,859	$ 18,626
Service and other revenue	13,112	12,764
Total revenue	36,971	31,390
Cost of revenue	14,279	12,268
Gross profit	22,692	19,122
Research and development costs	13,897	12,392
Sales and marketing expenses	16,461	14,478
General and administrative expenses	16,498	11,986
Operating loss	(24,164)	(19,734)
Other income (expense):		
Other expense, net	(146)	(40)
Interest income	1,213	1,390
Interest expense	(2,388)	(518)
Net loss before income taxes	(25,485)	(18,902)
Income tax expense	55	12
Net loss	$ (25,540)	$ (18,914)
Net loss per share attributable to common stockholders:		
Basic and diluted	$ (0.90)	$ (0.70)
Weighted average shares outstanding:		
Basic and diluted	28,315,254	27,027,692

CLEARPOINT NEURO, INC.

Consolidated Balance Sheets

(in thousands, except for share and per share data)

	December 31,	
	2025	**2024**
ASSETS		
Current assets:		
Cash and cash equivalents	$ 45,923	$ 20,104
Accounts receivable, net	6,549	4,713
Inventory, net	8,359	6,863
Prepaid expenses and other current assets	2,769	1,683
Total current assets	63,600	33,363
Property and equipment, net	2,621	2,005
Operating lease, right-of-use assets	8,430	3,086
Goodwill	7,472	—
Intangible assets, net	13,922	—
Other assets	1,702	735
Total assets	$ 97,747	$ 39,189
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 1,256	$ 1,340
Accrued compensation	4,360	4,885
Other accrued liabilities	2,786	1,450
Operating lease liabilities, current portion	694	557
Contract liabilities, current portion	1,669	2,121
Total current liabilities	10,765	10,353
Operating lease liabilities, net of current portion	8,461	3,011
Contract liabilities, net of current portion	581	436
Long-term notes payable, net	49,077	—
Deferred tax liabilities, net	354	—
Other long-term liabilities	489	—
Total liabilities	69,727	13,800
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2025 and 2024; none issued and outstanding at December 31, 2025 and 2024	—	—
Common stock, $0.01 par value; 90,000,000 shares authorized at December 31, 2025 and 2024; 29,368,760 and 27,617,415 shares issued and outstanding at December 31, 2025 and 2024, respectively	294	276
Additional paid-in capital	238,995	216,483
Shares to be issued	5,641	—
Accumulated deficit	(216,910)	(191,370)
Total stockholders' equity	28,020	25,389
Total liabilities and stockholders' equity	$ 97,747	$ 39,189

CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(in thousands)

	Year Ended December 31,	
	2025	**2024**
Cash flows from operating activities:		
Net loss	$ (25,540)	$ (18,914)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Allowance for credit losses (recoveries)	21	(296)
Depreciation and amortization	814	980
Amortization of intangible assets	168	—
Share-based compensation	8,180	6,907
Payment-in-kind interest	908	—
Amortization of debt issuance costs and original issue discounts	83	51
Amortization of lease right of use assets, net of accretion in lease liabilities	1,255	923
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	(268)	(1,206)
Inventory, net	(103)	743
Prepaid expenses and other current assets	(397)	262
Other assets	(195)	(39)
Accounts payable and accrued expenses	(7,520)	3,105
Lease liabilities	(1,012)	(869)
Contract liabilities	(319)	(597)
Net cash flows from operating activities	(23,925)	(8,950)
Cash flows from investing activities:		
Cash acquired in business combination, net of cash paid	1,137	—
Purchases of property and equipment	(522)	(275)
Net cash flows from investing activities	615	(275)
Cash flows from financing activities:		
Proceeds from offerings of common stock, net of offering costs	3,263	16,149
Proceeds from issuance of notes payable, net of financing costs and discount	48,086	—
Repayment of 2020 senior secured convertible note	—	(10,000)
Proceeds from stock option exercises	127	21
Payments for taxes related to net share settlement of equity awards	(1,856)	(424)
Proceeds from issuance of common stock under employee stock purchase plan	559	443
Net cash flows from financing activities	50,179	6,189
Net change in cash, cash equivalents and restricted cash	26,869	(3,036)
Cash, cash equivalents and restricted cash, beginning of year	20,104	23,140
Cash, cash equivalents and restricted cash, end of year	$ 46,973	$ 20,104
Cash and cash equivalents	45,923	20,104
Restricted cash included in other current assets and other assets, non-current	1,050	—
Total cash, cash equivalents and restricted cash	$ 46,973	$ 20,104
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash paid for:		
Income taxes	$ 69	$ 62
Interest	$ 908	$ 480

DISCLAIMER

Statements in this presentation and discussion concerning ClearPoint Neuro's (the "Company's") plans, growth, and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance; the continued development, anticipated timing, and potential commercial opportunity of the Company's pipeline of products and services under development, including its proprietary Robotic Neuro-Navigation platform System, cell and gene therapy delivery devices and routes of administration, software modeling and navigation tools, and preclinical service capabilities; the expected future role of the Company's products and services in addressing unmet needs in neurological diseases and the potential market opportunity for therapies targeting those indications; the Company's belief about the outcome of regulatory interactions with respect to its biotech Partners' therapies, the benefits of regulatory expedited review with respect to accelerating the timing of commercialization of such therapies, and the market potential for such therapies; the size of total addressable markets or the market opportunity for the Company's products and services, including for the PRISM Laser Therapy System; the Company's preclinical CRO facility, the IRRA*flow* Active Fluid Exchange System, and the Company's navigation technology; the anticipated adoption of the Company's products and services for use in the delivery of gene and cell therapies; the Company's ability to scale its operations, commercialization, and increase utilization of its products in neurosurgical centers; the Company's 4-Pillar Product pipeline; the Company's future looking 4-phase strategy; the Company's four and five pillar growth strategy for 2026 and beyond; the Company's expectations for revenues, market share, operating expenses, and management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's biotech Partners' risks related to the ongoing conduct of their clinical studies, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data becomes available that results in a different interpretation then the data already released for gene and cell therapies; risks related to interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval of the biotech Partners' therapies; the limitation or modification of the FDA's eligibility and criteria for its expedited review programs with respect to such therapies; the commercialization and acceptance of gene and cell therapies; the Company's biotech Partner's continued use of the Company's products and services in their delivery of gene and cell therapies; the Company's ability to maintain its current relationships with its biotech Partners or enter into relationships with new partners; the Company's ability to continue to build and maintain the infrastructure and personnel needed to allow for widespread adoption of intracranial administration of gene and cell therapies; risks inherent in the research, development, and regulatory approval of the Company's new pipeline products; the future market for preclinical services and the investment required to expand such services, which could divert resources from the Company's other business operations; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company's failure to integrate IRRAS into its business in accordance with expectations; deviations from the expected market potential of the IRRAS products; diversion of management's attention on the IRRAS proposed transaction; macroeconomic and inflationary conditions; regulatory and policy uncertainty; the introduction of or changes in tariffs, sanctions, or trade barriers; changes in monetary policy; geopolitical trends, such as instability, protectionism and economic nationalism; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the availability of additional funding to support the Company's research and development programs and commercialization efforts; the ability of the Company to manage the growth of its business; and the Company's ability to attract and retain its key employees. For a detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Biologics and Drug Delivery





Neuro Navigation and Robotics*



Ablation Therapy and Access

Neurocritical Management

*Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance.

CLEARPOINT® NEURO

OUR COMPANY

We Enable Delivery of Both Drug and Device Therapies by Offering Precise Navigation to the Brain and Spine

Our Unique Platform Includes Proven Clinical Products Used by Hospitals and Neurosurgeons, and Drug Development Services Used by BioPharma Partners

Our Company

The Future of Neuro Biologics and Drug Delivery **is Here Today**

More than **30 Million people** in the U.S. alone are estimated to suffer from **severe and debilitating neurological disorders.**

Neurological diseases cost Americans nearly $800 Billion annually. To reduce these costs, we must improve both the therapies and the access to care.



30 Million Patients Indicated in the U.S.

30 Million Patients
U.S. prevalence pool

<300k treated to date with minimally-invasive neurosurgery
<1% penetration

ClearPoint Neuro believes that biologics and drug delivery, including cell and gene therapies, will be the answer and that our minimally invasive tools will make these therapies accessible.

Prevalence estimates are based on publicly available sources. Categories shown are representative and may not be mutually exclusive.

The Future of Neuro Biologics and Drug Delivery **is Here Today**

Of those 30 million patients, 2.1 million in the U.S. alone have disorders where a ClearPoint BioPharma Partner has already been accepted for FDA expedited review.



AskBio · Aspen Neuroscience · AVIADOBIO · BlueRock Therapeutics · kenai therapeutics · NEURONA THERAPEUTICS · PTC Therapeutics · REGENXBIO · SIREN Biotechnology · uniQure

ClearPoint Neuro has 60+ Active Pharma Partners, with 10+ programs accepted for FDA expedited review. In 2024, the first gene therapy delivered directly to the brain was approved.

FDA NEWS RELEASE

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

For Immediate Release: November 14, 2024

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency.

Importantly, this gene therapy is labeled as a **combination product** with the ClearPoint SmartFlow Neuro Cannula

The FDA also authorized the SmartFlow Neuro Cannula, an infusion tube inserted into a target in the brain (parenchymal tissue), to deliver Kebilidi. The SmartFlow Neuro Cannula is currently the only FDA authorized device indicated for use to administer Kebilidi. The FDA granted authorization of the SmartFlow Neuro Cannula to ClearPoint Neuro, Inc.

Our Company

Our 4-Phase Strategy Positions ClearPoint for Decades of Growth

2010 – 2019

1 | DESIGN. DISCOVERY.

EXTEND OUR LEAD WITH A UNIQUE DRUG DELIVERY ECOSYSTEM DESIGNED FOR CELL AND GENE THERAPY

Our one-of-a-kind drug delivery platform including neuro navigation, predictive modeling, co-labeled delivery devices, infusion monitoring software and expert clinical case support has become the leading choice by biopharma developers

2020 – 2025

2 | FUNDED. FOUNDATION.

GROW OUR ACTIVE INSTALLED BASE OF 150+ LEADING GLOBAL INSTITUTIONS AND ADD PROCEDURAL CAPACITY

With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expansive IP portfolio has given us a mature foundation on which to build

2026+

3 | FAST. FORWARD.

LEVERAGE OUR EXISTING PORTFOLIO TO PENETRATE A $1B EXISTING MARKET OPPORTUNITY TODAY

Our current products and pipeline, combined with our growing commercial reach will continue to compete in these four existing markets;

1) Biologics & drug delivery,
2) Neuro navigation & robotics,
3) Ablation therapy and access,
4) Neurocritical management,

Our next goal is to earn 20% share, generate $200m in annual revenue

2026+

4 | ESSENTIAL. EVERYWHERE.

BUILD A NEW $10B MARKET ALONGSIDE OUR 60+ BIOPHARMA PARTNERS AND DIVERSIFIED ACROSS 15+ INDICATIONS THAT INCLUDES DRUGS THAT ARE CO-LABELED WITH CLEARPOINT TECHNOLOGY

More than 10 of our partners have now been accepted for FDA expedited review and are leveraging our unique ecosystem, clinical trial experience, and proven global regulatory leadership

Our next goal is to treat just 1% of patients with these indications under expedited review, generate another $300m in annual revenue

Design. Discovery.

This Unique ClearPoint Ecosystem Has Been Years in the Making

ClearPoint Neuro embraced the unmet need in neuro biologics and drug delivery and has invested more than $200m over the past 15 years to build a substantial headstart and leadership position.

This expansive platform has been used in more than 10,000 procedures to date and has regulatory approvals across 34 countries and counting.*

We are positioned to benefit from the expanded use of our delivery platform to include future cell and gene therapies, new DBS and BCI indications, second generation laser ablation therapy, and more advanced approaches to neurocritical fluid management.



Data on file

*Not all products cleared or approved in all territories.

Funded. Foundation.

Our Installed Base Has Grown to More than 150 Active Global Centers

Over 170 employees worldwide focused exclusively on Neuro



Active ClearPoint Installation
(Additional Sites in Asia, EMEA, LATAM)

Funded. Foundation.

~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology

US News & World Report Best Neurology/Neurosurgery Hospitals 2025-2026
are recognized for excelling in the treatment of complex, high-risk neurological specialty cases.

Evaluation Criteria

45%	Outcomes
35%	Structure
12%	Process / Expert Opinion
5%	Patient Experience
3%	Public Transparency

- UCSF Medical Center
- New York-Presbyterian Hospital-Columbia and Cornell
- Rush University Medical Center
- Northwestern Memorial Hospital
- Johns Hopkins Hospital
- Hospital of University Pennsylvania
- UT Southwestern Medical Ctr
- Massachusetts General Hospital
- Stanford Health Hospital
- Cleveland Clinic
- UCLA Medical Center
- Houston Methodist Hospital
- Brigham & Women's Hospital
- Barnes-Jewish Hospital
- Cedars-Sinai Medical Center
- Mayo Clinic Arizona
- Mayo Clinic Florida
- Advent Health Orlando
- Keck Medical Center of USC
- Thomas Jefferson University
- UC Davis Medical Center
- UCSD Jacobs Medical Center
- University of Michigan
- Mount Sinai West
- University of Kansas
- Emory University Hospital
- Hackensack Meridian Health
- Corewell Beaumont University
- Yale University Hospital
- Ohio State University – Wexner
- University of Alabama at Birmingham
- University of Minnesota
- Barrow Institute
- Duke University Hospital
- University of Wisconsin, Madison
- Tampa General Hospital
- UC Irvine Medical Center
- Baptist Health Miami Hospital
- Ochsner Medical Center
- Penn State Health Milton
- Inova Fairfax Hospital
- Oregon Health & Science University
- University of Colorado Aurora
- Henry Ford Health
- University of North Carolina
- Froedtert Hospital
- Ohio Health Riverside
- University of Utah
- Georgetown University

https://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery - Posted July 29, 2025
Methodology components and weights summarized from publicly described Best Hospitals specialty ranking methodology (2025–2026 cycle; specialty-specific adjustments may apply).

Funded. Foundation.

Stress-Tested QMS and Operations

We have invested in our Research & Development, Quality and Manufacturing infrastructure to build confidence for both hospitals and biopharma partners

We bring **medical device expertise and regulatory combination product acumen** to pharmaceutical companies

ClearPoint Neuro assets available to our partners:

- HQ & training facility in Solana Beach, CA
- Advanced Research Laboratory in Torrey Pines, CA
- R&D and manufacturing facility in Carlsbad, CA
- ISO 13485 / MDSAP / EU MDR certified QMS
- Proven audit history with pharma partners, FDA and global regulatory body inspections

Funded. Foundation.

Growth Continues Today While We Prepare for Commercial Drug Approvals

HEADQUARTERS
Solana Beach, CA

R&D, MANUFACTURING
Carlsbad, CA

ADVANCED RESEARCH LABORATORIES
Torrey Pines, CA

2025 REVENUE
$37.0m (A)

GROSS MARGIN
61% (A,B)

PATENTS ISSUED
130+ (C)

CASH & CASH EQUIVALENTS
$45.9m (A)

EMPLOYEES
170+



*All Annual Totals in Millions

(A) For the year ended December 31, 2025
(B) For the Trailing Twelve Months (TTM)
(C) Including owned and licensed patents

Funded. Foundation.

Experienced Leadership in Place

EXECUTIVE LEADERSHIP TEAM

Proven industry operators with decades of experience in medical devices, biopharmaceuticals, and clinical research.

Joe Burnett
President & Chief Executive Officer

Danilo D'Alessandro
Chief Financial Officer

Jeremy Stigall
Chief Business Officer

Mazin Sabra
Chief Operating Officer

Paul Larson, MD
Chief Medical Officer

Ellisa Cholapranee
General Counsel

Megan Faulkenberry
Senior Vice President of Quality

Rob Korn
Senior Vice President of Sales

Mary McNamara-Cullinane
Senior Vice President of Regulatory Affairs

Tim Orr
Vice President of Software Development

Lyubomir Zagorchev, PhD
Vice President of Clinical Science & Applications

Ernesto Salegio, PhD
Vice President of Translational & Pre-Clinical Research

Fast. Forward.

Our 4-Pillar Growth Strategy

FAST. FORWARD.

Our **Fast. Forward.** 4-Pillar Growth Strategy is to **Win 20% of an Existing $1.0B Global Market Opportunity, Generate $200m in Annual Revenue,** and to **Achieve Cash Breakeven and Profitability Along the Way**

Collective $1.0B Existing Market Opportunity Today

Increasing Global Scale with Clearances in 34 Countries Worldwide*

*Not all products cleared or approved in all territories.

Fast. Forward.

Pillar 1: Pre-Commercial Biologics & Drug Delivery

CLEARPOINT ADVANCED LABORATORIES
Pre-Commercial Biologics & Drug Delivery

$300m+
Existing Market

ClearPoint Neuro currently offers a boutique, neuro-focused CRO complete with device co-development services, pre-clinical testing capabilities, and validated clinical trial products to support and de-risk our more than 60 active pharma partners and generate revenue before reaching the drug commercialization stage.

Combining Services & Technology

Benchtop Testing

- Device compatibility testing
- Custom device development
- Delivery system validation
- Performance assessment

Preclinical Studies



- Running preclinical studies
- Surgical planning & strategy
- Dosing & surgical expertise
- Post-procedure analysis

Hardware

Leverage Both Commercial and In-Development Delivery and Navigation Tools

Software



SmartFlow Software & Biophysical Modeling in Collaboration with NE Scientific

Fast. Forward.

Pillar 2: Neuro Navigation & Robotics

CLEARPOINT NAVIGATION SYSTEM
Neurosurgery Navigation & Robotics

$125m+
Existing Market

ClearPoint will provide unmatched flexibility by having a single pre-planning software offering several workflows deployed via either MRI, iCT and eventually Robotics. This strategy balances the consistency of delivery that biopharma partners desire with the optionality and adaptability for surgeons to choose their desired technique.

Pre-Planning & Navigation Software



Select Optimal Delivery Method

SmartFrame XG and Accessory Kit

SmartFrame OR and ClearPointer Optical Wand



ClearPoint Robotic Platform using the KUKA LBR Robotic Arm

*Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance.

Fast. Forward.

Pillar 3: Laser Therapy & Access

CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM

Laser Ablation Therapy & Access

$75m+ Existing Market

ClearPoint Prism is a mobile laser therapy system featuring innovative non-cooled applicator technology that simplifies setup, reduces power and potentially ablation time, and enables efficient workflows. Surgeons can capitalize on workflow efficiency and total system accuracy when Prism is combined with ClearPoint Navigation.

The Velocity^{ALPHA} MR High Speed Surgical Drill System is a versatile cutter system designed to reduce procedure times in both the MRI suite and the operating room.

CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM

With Optional ClearPoint Navigation Synergies

One Room

One System

One Team

Velocity^{ALPHA} MRI Conditional Power Drill

A Versatile Power Solution for SmartFrame in the MRI and OR

adeor MEDICAL

Fast. Forward.

Pillar 4: Neurocritical Management

IRRA*flow*®
Neurocritical Care & Active CSF Exchange

$500m+
Existing Market

ClearPoint's recent acquisition of IRRAS expands the portfolio with a unique and disruptive solution for neurocritical care and intracranial fluid management. IRRA*flow* enables active irrigation and controlled drainage of hemorrhage, toxins, and clots to therapeutically treat intracranial pathologies.

IRRA*flow*® Active Fluid Exchange System Components

IRRA*flow* Dual-Lumen Catheter



IRRA*flow* Tube Set & Intelligent Digital Cassette



IRRA*flow* Control Unit & Drainage Collection Bag

Fast. Forward.

Clear and Continued Investment in ClearPoint's 4-Pillar Product Pipeline

	1H 2026	2H 2026	1H 2027	2H 2027	2028+
1 CLEARPOINT ADVANCED LABORATORIES	• CAL Facility Operational • Radiopharma Formulation	• MRI/CT Imaging Live • GLP Study Capable • Cell Culture Capability	• PET/SPECT Imaging Live • Radiolabeling Active • Histopathology Active	• Bioanalytic Lab Active • Pathology Lab Active • Hot Cell F-18 Radiochemistry	• Translational Models for tumor, stroke and spinal cord injury
2 CLEARPOINT NAVIGATION SYSTEM	• CE Mark for 3.x Software • Global Installed Base with OR iCT capability	• SmartFrame Accessory Kit • Pre-Clinical Robotic System Active at the CAL	• Harmony 1.0 Software • Sub-Nuclei Segmentation	• SmartFrame Duet • Maestro CT	• Harmony 2.0 Software • Robotic System • DBS/BCI Area of Activation • Non-Rigid Fusion
3 CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM	• 1.5T Compatibility	• Velocity MRI Power Drill	• Philips MRI Compatibility • Interoperable 3D Damage Model	• CE Mark Prism System • 3D Thermal Modeling Study Initiated	• Predictive Ablation Software • Spine LITT Data Readout
4 IRRAflow®	• Shoreline Software • Cranial Access Bolt	• IRRA*flow* Dart • Cranial Access Bolt Kit	• ARCH RCT Data Readout • Next Gen IRRA*flow* Catheter	• Subdural Indication • IRRA*flow* Rapid Evacuation System	• VASH Trial Data Readout • CRYSTAL Registry Readout • Bedside Navigation System

Our **Fast. Forward.** 4-Pillar Growth Strategy is to **Win 20% of an Existing $1.0B Global Market Opportunity, Generate $200m in Annual Revenue,** and to **Achieve Cash Breakeven and Profitability Along the Way**

4 NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE
Expand Existing Portfolio Into Multiple New Indications
Launch Shoreline Software, Cranial Bolt, IRRA*flow* Dart, Next-Gen IRRA*flow* Catheter and a Subdural Hemorrhage Catheter Kit

3 LASER ABLATION THERAPY & ACCESS
Add Ablation Coverage & AI Predictive Thermal Modeling Software
Launch MRI Conditional Power Drill for Faster Procedure Times

2 NEUROSURGERY NAVIGATION AND ROBOTICS
Expand into the Operating Room w/ 3.0 Software, ClearPoint Duet, and Robotics
Launch Maestro CT, sub-nuclei segmentation, Non-Rigid Fusion, Area-of-Activation Harmony Software

1 PRE-COMMERCIAL BIOLOGICS & DRUG DELIVERY
Expand Neuro Pre-Clinical CRO Services Portfolio and Capacity including larger GLP Study Capability
Expand Partnerships to Include Co-Development, Commercial Pricing, Drug Clinical Milestones & Royalty Based Agreements
Execute on Development Pipeline for Drug Infusion Monitoring/Modeling, Cell Therapy Actuation, Indwelling Catheters and Spinal Routes of Administration

2026+

Essential. Everywhere.

What Does it Mean to be **Essential** to Future of Cell and Gene Therapy?

ESSENTIAL. EVERYWHERE.

It starts by being **unique**.

Our **Essential. Everywhere.** Strategy is to **build a new market from the ground up** where our unique ecosystem plays an essential role and enables 20,000 annual Cell & Gene Therapy procedures.

Our Goal is to create the capacity for 20,000 CGT patients per year and generate an additional $300m annually.

*Not all products cleared or approved in all territories.



Increasing Global Scale with Clearances in 34 Countries Worldwide*

Essential. Everywhere.

Our Unique Ecosystem Will Play An Essential Role for Cell and Gene Therapy



A.I. Derived Patient and Tissue Specific Segmentation

+



Therapy and Patient Specific Biophysics Modeling Tools

+

Comprehensive Pre-Planning Navigation Software Modules

+

Flexible Options for Surgeon Selected Navigation Including Frames, Robotics

+

Multiple Biologic Specific & Co-Labeled Routes-of-Administration

+



Confirmatory Volumetric Dosing Data for Quality of Delivery Documentation

Every Step Fully Supported by a Team of 30+ Expert Field-Based Clinical Specialists

All products in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance.

Essential. Everywhere.

ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials



...and more than 15 additional programs that are undisclosed and in preclinical development.

Essential. Everywhere.

10+ Programs Are Already Under FDA Expedited Review and Enrolling



Essential. Everywhere.

Building Surgical Experience and Capacity to Prepare for Drug Commercialization



Existing CLPT Navigation Site

Experienced CLPT Navigation Site and Participant in Active CGT Trial



Our Company

Our 4-Phase Strategy Positions ClearPoint for Decades of Growth

2010 – 2019

1 | DESIGN. DISCOVERY.

EXTEND OUR LEAD WITH A UNIQUE DRUG DELIVERY ECOSYSTEM DESIGNED FOR CELL AND GENE THERAPY

Our one-of-a-kind drug delivery platform including neuro navigation, predictive modeling, co-labeled delivery devices, infusion monitoring software and expert clinical case support has become the leading choice by biopharma developers

2020 – 2025

2 | FUNDED. FOUNDATION.

GROW OUR ACTIVE INSTALLED BASE OF 150+ LEADING GLOBAL INSTITUTIONS AND ADD PROCEDURAL CAPACITY

With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expansive IP portfolio has given us a mature foundation on which to build

2026+

3 | FAST. FORWARD.

LEVERAGE OUR EXISTING PORTFOLIO TO PENETRATE A $1B EXISTING MARKET OPPORTUNITY TODAY

Our current products and pipeline, combined with our growing commercial reach will continue to compete in these four existing markets;

1) Biologics & drug delivery,
2) Neuro navigation & robotics,
3) Ablation therapy and access,
4) Neurocritical management,

Our next goal is to earn 20% share, generate $200m in annual revenue

2026+

4 | ESSENTIAL. EVERYWHERE.

BUILD A NEW $10B MARKET ALONGSIDE OUR 60+ BIOPHARMA PARTNERS AND DIVERSIFIED ACROSS 15+ INDICATIONS THAT INCLUDES DRUGS THAT ARE CO-LABELED WITH CLEARPOINT TECHNOLOGY

More than 10 of our partners have now been accepted for FDA expedited review and are leveraging our unique ecosystem, clinical trial experience, and proven global regulatory leadership

Our next goal is to treat just 1% of patients with these indications under expedited review, generate another $300m in annual revenue